Passage BIO, Inc. — Investor Relations & Filings
Filings indexed
414
across all filing types
Latest filing
2026-05-27
Regulatory Filings
Country
US
United States of America
Listing
US
PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| FORM 8-K | 2026-05-26 | English | |
| 10-Q - Passage BIO, Inc. (0001787297) (Filer) | 2026-05-12 | English | |
| 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-28 | English | |
| 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-20 | English | |
| ARS - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 47845684 | 8-K | 2026-05-27 | English | ||
| 47059730 | FORM 8-K | 2026-05-26 | English | ||
| 45232728 | 10-Q - Passage BIO, Inc. (0001787297) (Filer) | 2026-05-12 | English | ||
| 37959866 | 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-28 | English | ||
| 34690715 | 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-20 | English | ||
| 33703026 | ARS - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English | ||
| 33703035 | DEF 14A - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English | ||
| 32979094 | 4 - Passage BIO, Inc. (0001787297) (Issuer) | 2026-03-18 | English | ||
| 32898268 | 10-K - PASSAGE BIO, INC. (0001787297) (Filer) | 2026-03-03 | English | ||
| 32898267 | 8-K - PASSAGE BIO, INC. (0001787297) (Filer) | 2026-03-03 | English | ||
| 13203760 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13203761 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13203762 | FORM 8-K | 2026-01-12 | English | ||
| 13203764 | Regulatory Filings 2026 | 2026-01-09 | English | ||
|
2025
1 filing
| |||||
| 13203763 | Director's Dealing 2025 | 2025-12-29 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMAGION BIOSYSTEMS LIMITED
Develops nanoparticle-based imaging for non-invasive cancer…
|
IBX | AU | Professional, scientific and te… |
|
IMCB PJSC
Biotechnology company specializing in personal stem cell ba…
|
GEMA | RU | Professional, scientific and te… |
|
Immuneering Corp
Clinical-stage oncology company developing medicines using …
|
IMRX | US | Professional, scientific and te… |
|
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Clinical-stage biotech developing dual-approach immuno-onco…
|
1541 | HK | Professional, scientific and te… |
|
IMMUNIC, INC.
Develops oral small molecule therapies for chronic inflamma…
|
IMUX | US | Professional, scientific and te… |
|
Immunovant, Inc.
Clinical-stage immunology company developing anti-FcRn anti…
|
IMVT | US | Professional, scientific and te… |
|
IMMUPHARMA PLC
Specialty biopharmaceutical company developing peptide-base…
|
IMM | GB | Professional, scientific and te… |
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
Passage BIO, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34849/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34849 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34849 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34849 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34849}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Passage BIO, Inc. (id: 34849)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.